Read More

AbbVie Earlier Announced European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease

AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had in

ABBV

Read More

Reported Late Tuesday, Mesoblast Announces Top-Line Long-Term Survival Results For Remestemcel-L From Its Pivotal Phase 3 Trial Through 4-Years In Children With Steroid-Refractory Acute Graft vs Host Disease

Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001 Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in

MESO